This Study Was a Prospective, One-arm Open Phase II Clinical Trial. A Systematic Review of the pCR of Apatinib in Combination With the Albumin Paclitaxel and Carboplatin Regimens for the Neoadjuvant Therapy of Triple-negative Breast Cancer, as Well as the Safety of Treatment

Clinical trial NCT03650738 · UNKNOWN

Trial details

NCT number: NCT03650738
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Systematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast Cancer

Start date: 2018-09-01
Primary completion: 2019-12-30
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.